The spindle assembly checkpoint (SAC) is required to block sister chromatid separation until all chromosomes are properly attached to the mitotic apparatus. The SAC prevents cells from entering anaphase by inhibiting the ubiquitylation of cyclin B1 and securin by the anaphase promoting complex/cyclosome (APC/C) ubiquitin ligase. The target of the SAC is the essential APC/C activator Cdc20. It is unclear how the SAC inactivates Cdc20 but most current models suggest that Cdc20 forms a stable complex with the Mad2 checkpoint protein. Here we show that most Cdc20 is not in a complex with Mad2; instead Mad2 is required for Cdc20 to form a complex with another checkpoint protein, BubR1. We further show that during the SAC, the APC/C ubiquitylates Cdc20 to target it for degradation. Thus, ubiquitylation of human Cdc20 is not required to release it from the checkpoint complex, but to degrade it to maintain mitotic arrest.
The proper control of mitosis depends on ubiquitin-mediated proteolysis of key regulators at the correct time 1 . Crucially, cyclin B1 and the anaphase inhibitor securin, which maintain cells in mitosis, must not be degraded until all the chromosomes are properly attached to the spindle. To achieve this, a conserved mechanism called the spindle assembly checkpoint (SAC) is activated by improperly attached kinetochores and prevents recognition of cyclin B1 and securin by the APC/C ubiquitin ligase 2 . A number of conserved proteins have been identified as components of the SAC, including Mad1, Mad2, Mad3/BubR1, Bub1, Bub3, Mps1 and the Aurora B kinase. The primary target of the SAC is the Cdc20/fizzy protein 3, 4 , which is an essential APC/C activator 5 . However, it is unclear how the SAC regulates Cdc20. Current models of the SAC propose that the Mad2 protein has a crucial role either to sequester Cdc20, or act in conjunction with the BubR1 and Bub3 proteins to form an inhibitor called the mitotic checkpoint complex (MCC) 2 . The prominence given to the Mad2-Cdc20 complex is understandable because the crystal structure of Mad2 bound to a Cdc20mimicking peptide predicts that Mad2 changes conformation [6] [7] [8] to bind Cdc20 tightly through a 'safety belt' mechanism 6, 8 , although another inhibitory complex comprised of BubR1 and Bub3 has also been identified 9, 10 .
Recently, it has been suggested that inhibitory complexes must be actively dissociated by ubiquitylation of Cdc20, mediated by the APC/C to turn off the SAC 11, 12 . By contrast, in Saccharomyces cerevisiase Cdc20 is ubiquitylated during the SAC to target it for destruction 13, 14 , and this degradation is important because overexpressing Cdc20 overcomes the SAC 13 .
Here, we have studied the mechanism by which the human SAC regulates Cdc20. In contrast to the prevailing models, we find that Cdc20 does not accumulate in a stoichiometric complex with Mad2, but primarily in a complex with BubR1 and Bub3. Moreover, although Cdc20 is ubiquitylated by the APC/C, this ubiquitylation is required to target Cdc20 for destruction to maintain the checkpoint and not to release Cdc20 from a checkpoint complex. Indeed, a non-ubiquitylatable form of Cdc20 overcomes the checkpoint. We suggest that the SAC is maintained through BubR1-Bub3 presenting Cdc20 to the APC/C as a substrate, and that the primary role of Mad2 is to generate the BubR1-Bub3-Cdc20 complex.
RESULTS

Cdc20 is degraded by the SAC
We set out to determine how the SAC inactivates Cdc20 in human cells and noticed that although Cdc20 levels seemed to remain constant during SAC arrest, they increased almost threefold on adding the proteasome inhibitor MG132 ( Fig. 1a ; Supplementary Information, Fig. S1a ), indicating that Cdc20 may be continually synthesized and degraded during the SAC. To test this, we inhibited protein synthesis by adding cycloheximide and found that the level of Cdc20 decreased substantially ( Fig. 1a, b ; Supplementary Information, Fig. S1b) . A time-course showed that the half-life of Cdc20 in nocodazole-or taxol-arrested cells was about 30 min ( Fig. 1b ). Cyclin B1 ( Fig. 1b ) and securin (data not shown) were also degraded in SAC-arrested cells with a half-life of about 1 h, as previously shown 15, 16 . Cdc20 levels did not change when we added rapamycin, which only inhibits cap (eIF4E)-dependent translation ( Fig. 1c ), suggesting that during mitosis, Cdc20 may be synthesized from an internal ribosome entry site (IRES). Blotting for phospho-S6 kinase showed that rapamycin had inhibited the mTOR pathway and was thus likely to have inhibited eIF4E-dependent translation (Fig. 1d) . We confirmed the checkpoint-dependent degradation of Cdc20 in a live-cell assay 15 using a yellow fluorescent protein (YFP)-Cdc20 fusion protein. YFP-Cdc20 retained the functional properties of Cdc20 as it rescued cells depleted of Cdc20 with short interfering RNA (siRNA), localized to kinetochores in mitosis 17, 18 and was degraded as cells exited mitosis. YFP-Cdc20 fluorescence levels immediately began to decline in prometaphase or metaphase cells when we activated the SAC with nocodazole ( Fig. 1e ). When we added nocodazole or taxol to interphase cells, YFP-Cdc20 began to be degraded only at nuclear envelope breakdown (NEBD; Fig. 1f ), and was stabilized by MG132 ( Fig. 1e, f) . Identical results were obtained when we assayed Cdc20 degradation in RPE cells ( Supplementary Information, Fig. S1b ).
Our observation that YFP-Cdc20 began to be degraded only after NEBD indicates that in response to the SAC, Cdc20 may be ubiquitylated by the APC/C, as this is the time when the APC/C recognizes its first mitotic substrates [19] [20] [21] . We tested this by depleting APC3 using siRNA ( Fig. 2a, b) , which inactivated the APC/C, as shown by stabilization of cyclin A, cyclin B1 and securin (D. Izawa and J.P., manuscript in preparation), and blocked cells in mitosis. In APC/C-depleted cells, endogenous Cdc20 and YFP-Cdc20 were stable in the presence of an active SAC ( Fig. 2a, c) . We confirmed that the SAC itself was required for Cdc20 degradation by depleting Mad2 using siRNA, which stabilized Cdc20 until cells exited mitosis ( Fig. 2d ).
An inactive Cdc20 cannot be degraded in response to the SAC Our observation that Cdc20 was targeted for degradation by the APC/C in response to the SAC raised the question of whether Cdc20 
Cdc20 is degraded in checkpoint-arrested cells. (a) HeLa cells were pre-synchronized in S phase and subsequently arrested in mitosis with nocodazole for 6 h. Cells were left untreated (control) or treated with either MG132 or cycloheximide (CHX) for 2 h. The levels of BubR1, Cdh1, Cdc20 and Mad2 were then determined by quantitative immunoblotting. Protein levels were normalized against actin and the bar diagrams show the levels of the indicated proteins, with the untreated sample set to 1. Data are mean ± s.d. (n = 3) (b) The levels of BubR1, Cdc20, cyclin B1 and Mad2 at 0, 20, 40, 60 and 120 min after addition of CHX to either nocodazole-or taxol-arrested cells (synchronized as in a) were analysed by ECL western blotting (whole blots are shown in Supplementary Information, Fig. S7 ). (c) The levels of Cdc20 and Mad2 at 0, 20, 40, 60 and 120 min after addition of CHX or rapamycin to nocodazole-arrested cells (whole blots are shown in Supplementary Information, Fig. S7 ). (d) The level of p70S6K phoshorylated on Thr 389 at 0, 30, 60 and 120 min following addition of rapamycin to asynchronous HeLa cells. (e, f) Degradation of YFP-Cdc20 in single cells. G2 phase HeLa cells were microinjected with a plasmid encoding YFP-Cdc20 and the fluorescence level assayed through mitosis. Note that the YFP-Cdc20 was encoded by cap-dependent mRNA, whose translation was repressed in mitosis. Therefore, we could assay degradation without CHX. Either nocodazole or MG132 was added at the times indicated. Nocodazole was added in prometaphase (e) and in G2 phase (f). Results for two different cells are shown, representative of ten cells in three independent experiments. activated its own destruction, or whether it was recognized by another APC/C Cdc20 complex. To analyse this, we ectopically expressed various Venus-tagged Cdc20 mutants and measured their degradation in nocodazole-treated cells ( Fig. 3 ). To bind the APC/C, Cdc20 requires isoleucine-arginine at its carboxy terminus and the C-box motif 22, 23 .
Mutating either of these motifs prevented (IR mutant) or considerably slowed down (C-box mutant) its degradation in SAC-arrested cells ( Fig. 3a, b ). Similarly, Cdc20 with a mutation in the Mad2-binding site (R132A) abrogated the SAC and was not degraded in the presence of nocodazole (Fig 3c) .
BubR1 and not Mad2 is the predominant partner of Cdc20 in SAC-arrested cells
Our interpretation of these results was that the SAC caused Cdc20 to activate its own ubiquitylation by the APC/C. To test this, we analysed the interactions between Cdc20, the APC/C and checkpoint proteins by size-exclusion chromatography and quantitative immunoblotting. We used nitrogen cavitation to lyse the cells, which solubilized more than 95% of Cdc20, the APC/C and the checkpoint proteins (Supplementary Information, Figs S4, S5), and measured the stoichiometry of protein complexes by calibrating our antibodies using recombinant proteins (Supplementary Information, Figs S1, S2). We used fluorescently labelled secondary antibodies and measured the signal on a LiCOR Odyssey scanner, which is linear over a 10,000 range and thus far more quantitative than ECL, although errors could be introduced during protein transfer, or in recognition by the primary antibody or binding between the primary and secondary antibodies). In either nocodazole-or taxol-arrested cells, the bulk of Cdc20 migrated in two large complexes, one with a relative molecular mass of 2,000,000 (M r 2,000K) and one of about 670K ( Fig. 4a ; Supplementary Information, Figs S3, S4). Quantitative immunoblotting ( Fig.4a ; Supplementary Information, Fig. S3a , b) and immunoprecipitations from peak fractions ( Fig. 4d ; Supplementary Information, Fig. S2 ) showed that the 2,000K complex contained the APC/C, BubR1 and Bub3, whereas the 670K complex contained BubR1 and Bub3, but no APC/C. Both complexes had very little Mad2, most of which migrated at a size that probably corresponds to free Mad2 ( Fig. 4 ; Supplementary Information, Figs S3, S4). From the amounts of proteins in immunoprecipitates of Cdc20 from the 2,000K and 670K complexes, we estimate that only about 5% of Cdc20 was bound to Mad2 in cells with an active checkpoint, whereas the molar ratio of BubR1 to Cdc20 was between 0.5 and 1 ( Supplementary Information, Fig. S2 ). Thus, the 670K complex we detected probably corresponded to the Bub3-BubR1-Cdc20 checkpoint complex identified in previous studies 9, 10 , rather than the MCC complex where Mad2, BubR1, Bub3 and Cdc20 were proposed to be present with 1:1:1:1 stoichiometry 24 .
When we blocked Cdc20 degradation with MG132, Cdc20 accumulated in both the 2,000K and 670K complexes ( Fig. 4b ) and immunoprecipitating the APC/C verified the increase in binding to Cdc20 ( Supplementary Information, Fig. S4 ). In addition, a third complex appeared running at approximately 200K, which was likely to be free Cdc20 as it did not co-migrate with any of the known Cdc20 partners (Mad and Bub proteins, the APC/C and the CCT chaperone complex that migrates at about 800K) 25 . Moreover, when we released the checkpoint by adding the Aurora B inhibitor ZM447439 to taxol-or nocodazole-treated cells 26 , but retained cells in mitosis by adding MG132, Cdc20 levels in the 670K complex decreased and more migrated as 'free' Cdc20 ( Fig. 4c ). Identical results were obtained when we analysed cells in which we released the checkpoint by washing out nocodazole in the presence of MG132 ( Supplementary Information, Fig. S4 ). The appearance of some Cdc20 not bound to checkpoint proteins upon the addition of MG132 indicated that preventing Cdc20 degradation caused Cdc20 to exceed the level of the BubR1-Bub3 complex, consistent with there being similar amounts of Cdc20 and BubR1 in SAC-arrested cells (1:1:1:3, Cdc20:BubR1:APC/C:Mad2, Supplementary Information, Fig. S2 ).
After releasing the checkpoint, the amount of BubR1 migrating with the APC/C decreased but the amount of Cdc20 bound to the APC/C remained the same (Fig. 4c ), perhaps corresponding to active APC/C Cdc20 .
These results are consistent with Cdc20 binding first to BubR1 to form the 670K complex when the checkpoint was active, and subsequently being presented to the APC/C as a substrate for ubiquitylation, thereby forming the 2,000K complex. By inhibiting degradation, we may have blocked this pathway, causing both the 2,000K and the intermediate 670K complex to accumulate. In support of this, the amount of Cdc20 and BubR1 bound to the APC/C increased when the proteasome was inhibited, whereas it decreased when cycloheximide was added ( Supplementary Information, Fig. S4 ).
As we did not find significant amounts of Mad2 bound to Cdc20, we assessed whether Mad2 is required for Cdc20 binding to BubR1, as in S. cerevisiase 27 , but that BubR1 is not required for binding between Mad2 and Cdc20. Indeed, we found that Mad2 siRNA caused a substantial decrease in the amount of Cdc20 bound to BubR1 in SAC-arrested cells maintained in mitosis with MG132, whereas BubR1 siRNA did not significantly alter the amount of Mad2 bound to Cdc20 ( Fig. 4f-h) .
A non-ubiquitylatable Cdc20 overrides the SAC
Our data indicate that ubiquitin-mediated degradation of human Cdc20, catalysed by the APC/C, is an important component for maintenance of the SAC. In contrast, ubiquitylation has recently been proposed not to target Cdc20 for degradation but to inactivate the SAC by releasing Cdc20 from a checkpoint complex 11, 12 . To determine whether ubiquitylation of Cdc20 is required to maintain or inactivate the SAC, we made a mutant RPE + wild-type Cdc20 0% (n = 10)
The ability of HeLa and RPE cells expressing wild-type or the Lys-less mutant of Cdc20 to overcome the SAC (NEBD, nuclear envelope breakdown; DMA, dimethylanasotron).
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of Cdc20 that could not be ubiquitylated, by changing all the lysines to arginines. This 'Lys-less' mutant of Cdc20 could not be ubiquitylated by the APC/C in vitro ( Fig. 5a ) but was functional as it could activate the APC/C ( Supplementary Information, Fig. S5a ) and rescue the mitotic arrest induced by Cdc20 siRNA (21 of 21 cells in three independent experiments), with a timing similar to that of wild-type Cdc20 (16 of 16 cells in three independent experiments, Supplementary Information, Fig. S5 ; the siRNA caused depletion of Cdc20 levels by more than 95% and caused 90% of cells to arrest in mitosis 28 .). Furthermore, the Lys-less mutant was able to bind appropriately and dissociate from checkpoint complexes (see below). The Lys-less mutant was more stable than wild-type Cdc20 ( Fig. 5 ) and, consistent with Cdc20 degradation being an integral part of the SAC, it was able to drive checkpoint-arrested HeLa (Fig. 5 , Table 1 ; Supplementary Information, Movie 1) and RPE (Table 1 ; Supplementary Information, Fig. S6 and Movie 2) cells out of mitosis, whereas wild-type Cdc20 expressed at similar levels could not. Furthermore, cells expressing the Lys-less mutant at lower levels than endogenous Cdc20 could initially establish the checkpoint but were unable to maintain it, whereas cells overexpressing wild-type Cdc20 by about 10-fold remained arrested. These results suggest an important role for ubiquitylation and degradation of Cdc20 in maintaining but not initially imposing the SAC.
To test directly whether APC/C-dependent ubiquitylation of Cdc20 was required to release the checkpoint proteins, we depleted the APC3 and APC11 subunits from cells by siRNA ( Fig. 6a ). As previously mentioned, this stabilized Cdc20 in SAC-arrested cells, consistent with the APC/C targeting Cdc20 for destruction (Figs 2, 6b). When we immunoprecipitated Cdc20 from control or APC/C-depleted cells with an active SAC, Cdc20 was bound to BubR1 and some Mad2, and inactivating the checkpoint with ZM447439 showed that there was no difference in the ability of cells with or without APC/C activity to release Cdc20 from Mad2 and BubR1 ( Fig. 6c, d ). Congruent with this, we found no difference in the ability of wild-type and the Lys-less Cdc20 mutant to be released from checkpoint complexes. We generated cell lines stably expressing FLAG-tagged wild-type or Lys-less Cdc20 under a tetracycline-inducible promoter and immunoprecipitated FLAG-Cdc20 from cells arrested with nocodazole plus MG132 using an anti-FLAG antibody. Although the Lys-less mutant bound more Mad2, BubR1 and APC3 (see Discussion) than did wildtype Cdc20, there was no difference in the ability of the wild-type and Lys-less mutant to dissociate from Mad2 and BubR1 upon addition of ZM447439 ( Fig. 6e, f ). Thus, we conclude that Cdc20 is ubiquitylated as part of the SAC to target it for destruction and not to release it from a checkpoint complex.
DISCUSSION
Here we have shown that the SAC maintains mitotic arrest by degrading Cdc20 as an APC/C substrate. To do this the SAC requires Mad2 but, in contrast to most current models of the checkpoint, we found that in human cells, the majority of Mad2 does not form a stable complex with Cdc20. Instead, Cdc20 mostly accumulates in a complex with BubR1 and Bub3 and this complex binds to the APC/C. In the absence of Mad2, however, Cdc20 does not bind to BubR1. Thus, our working model ( Fig. 7) is that Mad2 acts catalytically to promote Cdc20 binding to BubR1, which in turn presents Cdc20 to the APC/C as a substrate, targeting it for degradation. Once the checkpoint is inactivated, Cdc20 no longer binds BubR1 and is free to activate the APC/C. This is consistent with data from S. cerevisiae, which show that Cdc20 is degraded during the spindle checkpoint 13, 14 , that the BubR1 homologue Mad3 has the greatest effect on Cdc20 stability, and that Mad2 is required for Cdc20 to bind to Mad3 (ref. 27 ). Furthermore, overexpressing Cdc20 in S. cerevisiae to threefold more than the endogenous level allows cells initially to arrest but not to remain in mitosis in the presence of spindle poisons 13 . Thus, maintaining the SAC by degrading Cdc20 may be conserved through evolution. Why Cdc20 degradation is necessary for maintenance of the checkpoint is not clear. The simplest explanation is that it prevents Cdc20 exceeding the level of the BubR1-Bub3 complex. This is feasible because Cdc20 and BubR1 are present at similar levels in the cell, and free Cdc20 appears when we add MG132 to SAC-arrested cells. It may not be as simple as this, however, because overexpressing wild-type Cdc20 by about 10-fold of endogenous levels does not override the checkpoint, and co-expressing BubR1 did not prevent the Lys-less mutant driving cells out of mitosis (although BubR1 may require Bub3 and/or another checkpoint component to act). As even small amounts of Lys-less Cdc20, which are unlikely to exceed the amount of Bub3-BubR1, do overcome the checkpoint, this may indicate that ubiquitylation inactivates Cdc20 directly. Although we cannot exclude the possibility that mutating all the lysines also altered other regulatory post-translational modifications, such as phosphorylation, a mutant version of Cdc20 in which all the Cdk consensus phosphorylation sites were altered to alanine did not override the SAC (data not shown). An alternative explanation relates to our observation that metaphase substrates of the APC/C can be degraded only if they are able to localize to specific places in the cell (F. Cooke, A. Hagting and J.P., manuscript in preparation). Therefore, overexpressing Cdc20 throughout the cell may not saturate the ability of the degradation machinery if it is only required to keep the levels of Cdc20 low in a specific location, whereas the Lys-less mutant could locally exceed the level of available checkpoint complexes. We have shown previously that the APC/C itself is recruited to improperly attached kinetochores by the checkpoint proteins 29 , and the data we present here could indicate that it is at unattached kinetochores that BubR1 presents Cdc20 to the APC/C as a substrate.
Our model has the advantage that it makes the checkpoint a dynamic system. We and others had shown previously that the SAC and APC/C activity are very tightly coupled: cyclin B1 destruction begins almost immediately after the checkpoint is turned off, and destruction stops almost immediately if the checkpoint is re-imposed 15 . As Cdc20 is continually synthesised during the SAC, activating or inactivating Mad2 should very rapidly alter APC/C activity by determining whether Cdc20 binds to BubR1 and becomes inactive, or remains free to activate the APC/C.
We propose that Mad2 catalyses the binding between Cdc20 and BubR1 (a similar conclusion was reached by Davenport et al. 30 but they used overexpressed protein in asynchronous cells). However, Mad2 does not have a recognizable catalytic domain and the crystal structures of Mad2 do not give immediate clues as to what this catalytic activity may be. The counter evidence, however, that Mad2 alone is a Cdc20 inhibitor, or forms a stoichiometric part of the Cdc20-inhibitory complex, is not strong. Mad2 is a poor inhibitor in vitro, and in Schizosaccharomyces pombe, Mad3/BubR1 is essential for Mad2 to block cells in mitosis 31 . There are also caveats to the method that defined the stoichiometry of the MCC 24 as 1:1:1:1 for Mad2:BubR1:Bub3:Cdc20, where cells were labelled with 35 S-methionine for only 6 h, which is insufficient to label long-lived proteins to equilibrium.
As the APC/C requires an activator to recognize its substrates, it will be interesting to know whether the same molecule of Cdc20 acts as both activator and substrate during the SAC, or whether Cdc20 bound to BubR1 requires another APC/C activator to be degraded.
We cannot yet distinguish between these possibilities but favour the idea that Cdc20 acts as both activator and substrate on the basis of the following evidence: first, siRNA treatment shows that the other APC/C activator, Cdh1, is not required for the SAC; indeed the mouse knockout shows that Cdh1 is not required for embryonic or somatic cell division 32 ; second, those motifs required for Cdc20 degradation during the checkpoint map to two classes ( Fig. 3) : the first are motifs in the Mad2-binding region (R132), and the second are the C-box and the C-terminal 'IR' motifs that are required for Cdc20 to bind and activate the APC/C. We propose that ubiquitylation and degradation are used to inactivate human Cdc20 and maintain the SAC, and not to turn off the checkpoint as recently proposed 11, 12 . Although we note that the Lys-less Cdc20 binds more Mad2, this is probably because we increased its affinity for Mad2 by changing a conserved lysine in the Mad2 binding site of Cdc20, as an arginine was preferred in this position in a phage-display screen for (a-c) Taxol-arrested cells (a) or taxol-arrested cells treated with MG132 for 2 h (b) or taxol-arrested cells treated with MG132 and ZM447439 for 2 h (c) were fractionated on a Superose 6 column. Fractions were probed for BubR1 (red), APC4 (green), Cdc20 (black) and Mad2 (grey), and analysed by quantitative immunoblotting. Values were normalized to the peak fraction value to obtain the profiles shown. The peak of Cdc20 indicated by an asterisk that appears between the APC/C and BubR1 peaks may be Cdc20 bound to the CCT chaperone, as it is not always seen (see Supplementary Information, Figs S4, S5.) Data are from one experiment representative of four or more independent experiments (whole blots for taxol-arrested cells shown in Supplementary Information, Fig. S7 . Note that this is probed sequentially for Cdc20, then BubR1 and then Mad2). (d, e) Cdc20 was immunoprecipitated from each of the two peak fractions from nocodazole-arrested cells (fraction 22 and fraction 28 see Supplementary Information, Fig. S4 ) and analysed for the presence of BubR1, APC3, Bub3 and Mad2 (d), and for APC/C subunits in the 2,000K complex (e). (f-h) Cells were treated with siRNA oligonucleotides against GAPDH, Mad2, BubR1 no. 1 (f) and no. 2 (g) for 72 h. During this time cells were released from a double-thymidine block and treated 9 h later with nocodazole and MG132 for 2 h. Cdc20 was immunoprecipitated from mitotic cells collected by shake-off. The amount of BubR1 and Mad2 associating with Cdc20 was determined by quantitative immunoblotting and normalized to the amount of Cdc20. The levels of BubR1 and Mad2 in GAPDH treated cells were set to 1 (h). Data are mean ± s.d. of three independent experiments in f using BubR1 RNAi oligonucleeotide no. 1, and the mean of two independent experiments in g using RNAi oligonucleotide no. 2. The whole blot is shown in Supplementary Information, Fig. S7 . In this case the blot was cut into three and the different panels probed for BubR1 or Cdc20 or Mad2.
Mad2-binding peptides 8 .We find no evidence that Cdc20 ubiquitylation is important to inactivate the checkpoint because the Lys-less form of Cdc20 that cannot be ubiquitylated is able to substitute for wild-type Cdc20 to promote mitotic exit with apparently normal timing, and is not impaired in its ability to be released from either Mad2 or BubR1 when the checkpoint is turned off. Ubiquitylation and degradation cannot be the only means by which Cdc20 is inactivated as cells expressing the Lys-less mutant initially delay in mitosis in the presence of microtubule toxins, and they progress at a similar rate as cells with wild-type Cdc20 through unchallenged mitosis, whereas cells without a SAC are greatly accelerated through mitosis 33 . Thus, Cdc20 may initially be inactivated when it is bound by Mad2 and incorporated into the BubR1 complex, but to maintain the arrest, Cdc20 must be ubiquitylated and degraded. The inactivation may be related to the way in which BubR1 binds and presents Cdc20 to the APC/C, such that Cdc20 targets itself for destruction; it is unlikely that in this state Cdc20 could activate the APC/C against another substrate.
Finally, we found that Cdc20 is continually synthesised in mitosis to replace the protein that is degraded. Cdc20 synthesis is insensitive to rapamycin, indicating that it may be translated from an IRES. There is considerable variation in the ability of tumour cell lines to maintain a checkpoint arrest 34 and it will be interesting to see whether this variability arises from differences in Cdc20 synthesis or degradation.
METHODS
Antibodies.
The following antibodies were used at the indicated dilution. Cdc20 Gel filtration column chromatography. Cells were collected by mitotic shake-off and washed twice with ice-cold PBS. Cells were resuspended in buffer A (140 mM NaCl, 30 mM Hepes pH 7.8, 6 mM MgCl 2 , 5% glycerol, 1 mM dithiothreitol (DTT), 1 µg µl -1 leupeptin, 1 µg µl -1 chymostatin, 0.2 µM microcystin, 3 mM ATP) at a 1:1 ratio of buffer to cells, and opened by nitrogen cavitation (1000 PSI, 30 min, Parr Instrument). Lysed cells were centrifuged at 20,000g for 10 min and 259,000g for 10 min before loading on Superose 6 PC 3.2/30 (GE Healthcare). The column was run at a flow of 25 µl min -1 in buffer B (140 mM NaCl, 30 mM Hepes 7.8, 5% glycerol, 1 mM DTT) and 50 µl fractions collected.
Quantitative immunoblotting. Primary antibodies were incubated with fluorescently labelled secondary antibodies and the fluorescence measured using a LI-COR Odyssey CCD scanner according to the manufacturer' s instructions (LI-COR Biosciences). We have tested this scanner and it is linear over a range of at least 1000; we calibrated our antibodies over a range from 5-150 ng, (see Supplementary Information, Fig. S2b ).
RNAi. The following ON-TARGETplus (Dharmacon) oligonucleotides were used: APC3-1 (GGAAAUAGCCGAGAGGUAAUU),
A P C 3 -2 ( C A A A A G A G C C U U A G U U U A A U U ) , APC11
(UCUGCAGGAUGGCAUUUAAUU),
Mad2 ( G G A A G A G U C G G G A C C A C A G U U ) , B u b R 1 -1 ( C A G A A A C G G G C A U U U G A A U U U ) ,
B u b R 1 -2 (GAUGGUGAAUUGUGGAAUA), Cdc20 (CGGAAGACCUGCCGUUACAUU) and GAPDH (D-001830-01). Cells were transfected with 100 nM of oligonucleotide using oligofectamin (Invitrogen). Cells were collected 72 h after transfection for immunoprecipitationss or analysed after 40 h by microscopy. In experiments where both APC3 and APC11 were knocked down, 75 nM of APC3-1 and 50 nM APC11 were used and cells transfected 72 and 48 h before collecting cells.
Cell culture. HeLa cells were maintained in advanced DMEM with 10% fetal bovine serum (FBS). RPE cells were maintained in DMEM (Sigma) with 10% FBS. For synchronization at the beginning of S phase, HeLa cells were treated with 2.5 mM thymidine or 2.5 mM thymidine followed by 2.5 µg ml -1 aphidicolin as described previously 35 . To block HeLa cells in prometaphase, nocodazole or taxol was added to a final concentration of 0.08 ng µl -1 . RPE cells were blocked in prometaphase using the Eg5 inhibitor dimethylanastron (10 µM; a gift from Athanassios Giannis, University of Leipzig, Germany). Cells used for immunoprecipitation or gel filtration analysis were treated for 12 h with nocodazole or taxol at 0.08 ng µl -1 after a single-or a double-thymidine block. Stable cell lines expressing wild-type FLAG -Cdc20 and Lys-less FLAG-Cdc20 were made using the Flp-In system (Invitrogen). The HeLa FRT cell line was a gift from Stephen Taylor. Protein synthesis was inhibited by adding cycloheximide to a final concentration of 20 µg ml -1 , or rapamycin (20 ng ml -1 ). Proteasomes were blocked by adding MG132 (10 µM).
In vivo dissociation of checkpoint proteins. APC3 and APC11 were knocked down and cells were syncronized by a double-thymidine protocol and released into taxol for 6 h. MG132 was added to cells and ZM447439 was added to one dish for 2 h. Cells were processed for Cdc20 immunoprecipitation as described.
APC3 APC11
Hsp70 CHX 0 120 0 120 Cdc20 Hsp70  Cdc20   BubR1   Mad2   GAPDH  GAPDH, ZM  APC3/11  APC3/11, ZM  GAPDH  GAPDH, ZM  APC3/11  APC3/ Dissociation of checkpoint proteins from Cdc20 does not require ubiquitylation of Cdc20. (a) Cells were treated with siRNA against GAPDH or siRNAs against APC3 and APC11 and immunoblotted for APC3, APC11. Hsp70 was used as a loading control. (b) Cells were treated as in a, arrested in mitosis with taxol and the stability of Cdc20 measured by adding cycloheximide (CHX). (c) Cells treated as in a were incubated with taxol for 6 h, the samples divided in two and MG132 or MG132 plus ZM447439 added. After 2 h, Cdc20 was immunopurified and the amount of BubR1 and Mad2 bound to Cdc20 determined by quantitative immunobloting (LC, antibody light chain). The whole blot is shown in Supplementary  Information, Fig. S7 . Note that the blot was cut into three and panels probed for BubR1 or Cdc20 or Mad2. (d) Quantification of the experiment shown in c. The level of bound BubR1 and Mad2 was normalized to the amount of Cdc20, and the level of BubR1 and Mad2 set to 1 in the samples without ZM447439. The mean ± s.d. of three independent experiments are shown. (e) HeLa cell lines stably expressing inducible FLAG-tagged wild-type or Lys-less Cdc20 were released from S phase, MG132 added 9 h later for 2 h and mitotic cells collected by shake-off. Samples were divided into two and 100 nM taxol plus MG132 added to both. After 1 h, FLAG-Cdc20 was immunopurified from one and ZM447439 (4 µM) added to the other 1.5 h before immunoprecipitating FLAG-Cdc20. The amount of BubR1, APC3 and Mad2 bound to Cdc20 was determined by quantitative immunobloting. (f) Quantification of the experiment shown in e with the level of BubR1 and Mad2 normalized to the amount of Cdc20 and the amount of BubR1 and Mad2 bound to Cdc20 set to 1 in experiments without ZM447439. Note that the Lys-less mutant of Cdc20 coimmunopurifies from taxol-treated cells with more BubR1 and Mad2 than does wild-type Cdc20. The mean ± s.d. of three independent experiments are shown. The amount of APC3 associated with Lys-less and wild-type Cdc20 decreased by 75% when the checkpoint was inactivated.
Stable cell lines expressing wild-type FLAG-Cdc20 or Lys-less FLAG-Cdc20 were synchronized by a double-thymidine approach and 9 h after release from the last thymidine treatment, MG132 was added for 2 h and mitotic cells were collected by shake-off and re-plated in the presence of taxol and MG132. After 1 h, FLAG immunoprecipitation was performed on half of the cells. To the remaining half of the cells, ZM447439 was added for 1.5 h before performing the FLAG immunoprecipitation.
Microscopy. Cells were incubated on the microscope using the delta T system (Bioptechs) and imaged by time-lapse fluorescence and DIC microscopy on a Leica DMIRBE or DMIR2 microscope equipped with a ×40 1.2 NA oil immersion lens. Cerulean/cyan fluorescent protein (CFP) and Venus/YFP were visualized using a JP5 filter set (Chroma) with excitation and emission filters in filter wheels (Lambda 10-3; Sutter Instrument) and a Cascade 512B or QuantEM CCD camera (Photometrics). Multiple cell positions were captured using a Corvus (Marzhauser) or H117 (Prior) stage. Shutters (Smart Shutter, Sutter Instrument), filter wheels, stages, microscopes and cameras were all controlled by SlideBook software (Intelligent Imaging Innovations). Images were captured at 3 min intervals and analysed using Slidebook. Images were exported to ImageJ to assemble into movies.
Immunoprecipitation. Complexes were immunoprecipitated with antibodies covalently coupled to Dynabeads (Invitrogen) using buffer B for incubation and washing. Cells for immunoprecipitation were lysed with 0.1% NP40 in buffer B for 30 min on ice and clarified by a 20,000g spin for 10 min.
Constructs. pET30a-Mad2: Mad2 was cloned into BamHI and HindIII of pET30a. pET30a-TEV-securin: TEV-securin was digested with BamHI and XhoI and inserted into BamHI-and XhoI-digested pET30a. pET30a-UbcH10: UbcH10 digested with BamHI and HindIII and cloned into pET30a digested with BamHI and HindIII. pET30a-APC10: APC10 digested with BamHI and EcoRI and cloned into pET30a digested with BamHI and EcoRI. pFAST-BAC BubR1: BubR1 digested with BamHI and SmaI was ligated into pFAST BAC B digested with BamHI and StuI. pFAST-BAC Cdc20, wild-type and Lys-less: Cdc20 digested with BglII and BamHI and cloned into BamHI digested pFAST-BAC. pPICZ His-Cdc20: Cdc20 cloned into EcoRI and NotI sites of pPICZ A. YFP-Cdc20: Cdc20 cloned into EcoRI and BamHI of pYFP-C1. pcDNA5/FRT/ TO FLAG-Cdc20 was cloned into BamHI site of modified pcDNA5/FRT/TO vector. Details of all clones are available on request.
Protein expression. Mad2, APC10, securin and UbcH10 were expressed in BL21 (DE3) RIL at 37 °C and purified by nickel affinity chromatography (Qiagen). APC10 was purified under denaturing conditions. Following nickel affinity chromatography, the His-Tag was removed from securin by TEV cleavage followed by removal of the tag by nickel affinity chromatography and chromatography on Superdex 75. Mad2 and UbcH10 were further purified by chromatography on Superdex 75. Cdc20 was expressed from pPICZ His-Cdc20 in Pichia pastoris and purified by nickel affinity chromatography followed by chromatography on Superdex 200. BubR1, wild-type Cdc20 and Lys-less Cdc20 were expressed in Sf9 cells according to the manufacturer's instructions (Invitrogen) and purified by nickel affinity chromatography.
In vitro ubiquitylation. The APC/C complex was purified with the APC4 antibody and eluted with the peptide antigen. Reactions were performed in 15 µl for 30 min at 37 °C in QA buffer (100 mM NaCl, 30 mM Hepes-KOH 7,8, 2 mM ATP, 2 mM MgCl 2, 0.1 µg µl -1 BSA, 1 mM DTT) and contained 0.02 µg µl -1 securin, 1.3 µg µl -1 ubiquitin, 0.05 µg µl -1 UbcH10, 0.015 µg µl -1 E1, 0.3 ng µl -1 Cdc20 and 1 µl APC/C.
RNAi resistant Cdc20 constructs.
To rescue RNAi-mediated depletion of Cdc20, we constructed wild-type Cdc20 and Cdc20 with all lysines changed to arginines by assembling chemically synthesized oligonucleotides as described previously 36 . DNA sequences were designed to be maximally different from the wild-type using Gene Designer software 37 .
Note: Supplementary Information is available on the Nature Cell Biology website. Spindle checkpoint model. Cdc20 is continually synthesized in mitosis and acts as an activator of the APC/C. However, in the presence of improperly attached kinetochores, Mad2 binds Cdc20 and this allows the loading of Cdc20 onto BubR1. Once BubR1 is bound to Cdc20, Mad2 is not required to sustain the binding and leaves the complex before or after the complex is presented to the APC/C. The APC/C then promotes ubiquitylation and degradation of Cdc20 to sustain the checkpoint.
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Figure S1 Cdc20 stability and level of proteins in nocodazole extract.
A) The amounts of the indicated proteins in cells arrested for 6 hrs in nocodazole, or arrested for 6 hrs and then released from nocodazole into MG132 for 2 hrs was determined using the LI-COR system. The level in nocodazole extract was set to 1. The mean+/-SD of 3 experiments is shown. B) RPE cells were arrested in mitosis with dimethylmonastron (DMA), treated with cycloheximide (CHX) and the level of Cdc20, BubR1, Mad2 and Hsp70 determined at 0, 30, 60, 90, 120, 150, 180 min. C) Coomasie stained gel of recombinant proteins used in D). The band at 55 kDa (arrowhead) was analyzed by mass spectrometry, which showed that it only contains Cdc20. (*) contaminant from Cdc20 preparation. D) The indicated amounts of recombinant BubR1, Cdc20, APC10 and Mad2 were run next to the indicated amounts of HeLa cell extract and assayed by quantitative immunoblotting. 
Figure S5
Wild-type or the K-less mutant of Cdc20 can rescue Cdc20depleted cells A) In vitro ubiquitination of securin stimulated by wt or K-less Cdc20. Securin was incubated with APC/C purified from nocodazole-arrested cells in the absence of recombinant Cdc20, or with recombinant wt or K-less Cdc20. The reactions were immuno-blotted for securin. B and C) G2 phase HeLa cells treated with siRNA to deplete endogenous Cdc20 were microinjected with a plasmid encoding YFPtagged wt or K-less Cdc20. Cells were followed by time-lapse DIC and fluorescence microscopy and total fluorescence intensity was plotted on a graph. The cells shown are representative of 8 (2 independent experiments) and 21 (2 independent experiments) cells that were microinjected respectively with YFP-Cdc20 or YFP-K-less Cdc20. 
